Literature DB >> 2461163

Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.

D C Eustice1, P A Feldman, I Zajac, A M Slee.   

Abstract

The mode of action of DuP 721 was investigated. This compound was active primarily against gram-positive bacteria, including multiply resistant strains of staphylococci. Although inactive against wild-type Escherichia coli, DuP 721 did inhibit E. coli when the outer membrane was perturbed by genetic or chemical means. Pulse-labeling studies with E. coli PLB-3252, a membrane-defective strain, showed that DuP 721 inhibited amino acid incorporation into proteins. The 50% inhibitory concentration of DuP 721 for protein synthesis was 3.8 micrograms/ml, but it was greater than 64 micrograms/ml for RNA and DNA syntheses. The direct addition of DuP 721 to cell-free systems did not inhibit any of the reactions of protein synthesis from chain initiation through chain elongation with either synthetic or natural mRNA as template. However, cell extracts prepared from DuP 721 growth-arrested cells were defective in initiation-dependent polypeptide synthesis directed by MS2 bacteriophage RNA. These cell-free extracts were not defective in polypeptide elongation or in fMet-tRNA(fMet)-dependent polypeptide synthesis stimulated by poly(G.U). We conclude, therefore, that DuP 721 exerts its primary action at a step preceding the interaction of fMet-tRNA(fMet) and 30S ribosomal subunits with the initiator codon.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461163      PMCID: PMC172380          DOI: 10.1128/AAC.32.8.1218

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Preparation and assay of purified Escherichia coli polysomes devoid of free ribosomal subunits and endogenous GTPase activities.

Authors:  T Girbés; B Cabrer; J Modolell
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

2.  TRANSFORMATION OF BIOCHEMICALLY DEFICIENT STRAINS OF BACILLUS SUBTILIS BY DEOXYRIBONUCLEATE.

Authors:  J Spizizen
Journal:  Proc Natl Acad Sci U S A       Date:  1958-10-15       Impact factor: 11.205

3.  The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis.

Authors:  D C Eustice; P A Feldman; A M Slee
Journal:  Biochem Biophys Res Commun       Date:  1988-02-15       Impact factor: 3.575

4.  Isolation and characterization of outer membrane permeability mutants in Escherichia coli K-12.

Authors:  S A Benson; A Decloux
Journal:  J Bacteriol       Date:  1985-01       Impact factor: 3.490

5.  Mechanisms of action of aminoglycoside antibiotics in eucaryotic protein synthesis.

Authors:  D C Eustice; J M Wilhelm
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

6.  Fidelity of the eukaryotic codon-anticodon interaction: interference by aminoglycoside antibiotics.

Authors:  D C Eustice; J M Wilhelm
Journal:  Biochemistry       Date:  1984-03-27       Impact factor: 3.162

7.  Polycations sensitize enteric bacteria to antibiotics.

Authors:  M Vaara; T Vaara
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

8.  Polycations as outer membrane-disorganizing agents.

Authors:  M Vaara; T Vaara
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

9.  Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.

Authors:  A M Slee; M A Wuonola; R J McRipley; I Zajac; M J Zawada; P T Bartholomew; W A Gregory; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 10.  Comparison of initiation of protein synthesis in procaryotes, eucaryotes, and organelles.

Authors:  M Kozak
Journal:  Microbiol Rev       Date:  1983-03
  10 in total
  28 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.

Authors:  M H Cynamon; S P Klemens; C A Sharpe; S Chase
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Agents that increase the permeability of the outer membrane.

Authors:  M Vaara
Journal:  Microbiol Rev       Date:  1992-09

4.  Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.

Authors:  Gabriela Grunder; Yvonne Zysset-Aschmann; Florence Vollenweider; Thomas Maier; Stephan Krähenbühl; Juergen Drewe
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay.

Authors:  R W Murray; R D Schaadt; G E Zurenko; K R Marotti
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

Authors:  C W Ford; J C Hamel; D M Wilson; J K Moerman; D Stapert; R J Yancey; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

7.  Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.

Authors:  Vandana Kalia; Rajni Miglani; Kedar P Purnapatre; Tarun Mathur; Smita Singhal; Seema Khan; Sreedhara R Voleti; Dilip J Upadhyay; Kulvinder Singh Saini; Ashok Rattan; V Samuel Raj
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.

Authors:  Eugene Skripkin; Timothy S McConnell; Joseph DeVito; Laura Lawrence; Joseph A Ippolito; Erin M Duffy; Joyce Sutcliffe; François Franceschi
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

9.  Pharmacokinetics of linezolid in subjects with renal dysfunction.

Authors:  Michael E Brier; Dennis J Stalker; George R Aronoff; Donald H Batts; Kristi K Ryan; Margaret O'Grady; Nancy K Hopkins; Gail L Jungbluth
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.